Sarepta Therapeutics

Amazing landscapes of Appenzell with impressive rock formations and beautiful lakes
Biotech

Dyne readies FDA push after DMD exon 51 med excels in trial

The drug “has the potential to transform the care of those living with DMD amenable to exon 51 skipping,” Dyne CEO John Cox said in a statement.
Eric Sagonowsky Dec 8, 2025 10:50am
Completing steps towards success checkmark on cubes symbolizing progress

Sarepta shares safety update on DM1 RNA med

Nov 24, 2025 4:00pm
sarepta building
Favicon Fierce Pharma

Sarepta, despite key trial flop, will seek full nod for DMD meds

Nov 4, 2025 7:56am
calendar
Favicon Fierce Pharma

Sarepta extends $700M debt to 2030 amid Elevidys uncertainty

Aug 21, 2025 10:52am
Stock exchange concept

Sarepta sells 9M Arrowhead shares for $174M cash

Aug 13, 2025 5:44pm
FDA
Favicon Fierce Pharma

Vinay Prasad is back at the FDA after last month's surprise ouster

Aug 9, 2025 12:22pm